System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Mouse Monoclonal to HLA-A2

BB7.2 (IgG2b)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  10-556-C025 azide free 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  10-556-C100 azide free 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  A4-556-T025 Alexa Fluor® 488 25 tests yes choose region PDF datasheetHTML datasheet buy
  A4-556-T100 Alexa Fluor® 488 100 tests yes choose region PDF datasheetHTML datasheet buy
  1P-556-T025 PE 25 tests yes choose region PDF datasheetHTML datasheet buy
  1P-556-T100 PE 100 tests yes choose region PDF datasheetHTML datasheet buy
  A6-556-T025 Alexa Fluor® 647 25 tests yes choose region PDF datasheetHTML datasheet buy
  A6-556-T100 Alexa Fluor® 647 100 tests yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order

Background

HLA-A2 (44 kDa) is the most frequent HLA-A allele in human ethnic populations. HLA-A, together with HLA-B and HLA-C, represent human HLA class I major histocompatibility (MHC) antigens. These intrinsic membrane glycoproteins are expressed on nucleated cells and noncovalently associate with an invariant beta2 microglobulin. They carry foreign determinants important for immune recognition by cytotoxic T cells, thus important for anti-viral and anti-tumour defence.

Specificity

The antibody BB7.2 recognizes an epitope at the C-terminus of alpha-2 helix and a turn on one of the underlying beta strands within the human HLA-A2 histocompatibility antigen.

Regulatory Status

Immunogen

HLA-A2 solubilised by papain

Species Reactivity:

  • Human

Negative Species:

Applications:

  • Flow Cytometry
  • Immunoprecipitation
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

Product Specific References

  • *Parham P, Brodsky FM: Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol. 1981 Dec;3(4):277-99. [Abstract]
  • *Pious D, Krangel MS, Dixon LL, Parham P, Strominger JL: HLA antigen structural gene mutants selected with an allospecific monoclonal antibody. Proc Natl Acad Sci U S A. 1982 Dec;79(24):7832-6. [Abstract] [Full Text]
  • *Krangel MS, Taketani S, Pious D, Strominger JL: HLA-A2 mutants immunoselected in vitro. Definition of residues contributing to an HLA-A2-specific serological determinant. J Exp Med. 1983 Jan 1;157(1):324-36." [Abstract] [Full Text]
  • *Taketani S, Krangel MS, Pious D, Strominger JL: Structural analysis of HLA-A2 antigen from immunoselected mutant 8.6.1: further definition of an HLA-A2-specific serological determinant. J Immunol. 1983 Dec;131(6):2935-8. " [Abstract]
  • *Brenner MB, McLean J, Yang SY, van der Poel JJ, Pious D, Strominger JL: Clonal T lymphocyte recognition of the fine structure of the HLA-A2 molecule. J Immunol. 1985 Jul;135(1):384-90. [Abstract]
  • *Scornik JC: HLA-A2 epitopes recognized by alloantibodies from broadly sensitized patients. Hum Immunol. 1987 Apr;18(4):277-85. [Abstract]
  • *Santos-Aguado J, Barbosa JA, Biro PA, Strominger JL: Molecular characterization of serologic recognition sites in the human HLA-A2 molecule. J Immunol. 1988 Oct 15;141(8):2811-8." [Abstract]
  • *Natali PG, Nicotra MR, Bigotti A, Venturo I, Marcenaro L, Giacomini P, Russo C: Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6719-23. [Abstract] [Full Text]
  • *Hogan KT, Brown SL: Localization and characterization of serologic epitopes on HLA-A2. Hum Immunol. 1992 Mar;33(3):185-92. [Abstract]
  • *Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJ, Kast WM: Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol. 1993 Jun;23(6):1215-9. [Abstract]
  • *Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ: HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol. 1993 Nov 15;151(10):5481-91. [Abstract]
  • *Barouch D, Davenport M, McMichael A, Reay P: A mAb against HLA-A2 can be influenced both positively and negatively by the associated peptide. Int Immunol. 1995 Oct;7(10):1599-605. [Abstract]
  • *Lee L, Loftus D, Appella E, Margulies DH, Mage M: A recombinant single-chain HLA-A2.1 molecule, with a cis active beta-2-microglobulin domain, is biologically active in peptide binding and antigen presentation. Hum Immunol. 1996 Aug;49(1):28-37. [Abstract]
  • *Forero L, Zwirner NW, Fink CW, FernŠndez-Viña MA, Stastny P: Juvenile arthritis, HLA-A2 and binding of DEK oncogene-peptides. Hum Immunol. 1998 Jul;59(7):443-50. [Abstract]
  • *Verdegaal EM, Huinink DB, Hoogstraten C, Marijnissen AK, Gorsira MB, Claas FH, Osanto S: Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient. Hum Immunol. 1999 Dec;60(12):1195-206. [Abstract]
  • *Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP: Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol. 2000 Sep;96(3):422-30. [Abstract]
  • *Liang B, Zhu L, Liang Z, Weng X, Lu X, Zhang C, Li H, Wu X: A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China. Cell Mol Immunol. 2006 Dec;3(6):453-8. [Abstract]
  • *And many other.
  • For research use only. Not for drug, diagnostic or other use.

    Related Products

  • Mouse IgG2b Isotype Control
  • Example Data

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIOīs term and conditions which are available at www.exbio.cz.
    Alexa Fluor®, Pacific Blue™ and Pacific Orange™ are registred trademarks of Molecular Probes Inc., Eugene, OR, USA. (licence label)
    DyLight® is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
    Cy™ and CyDye™ are registered trademarks of GE Healthcare.
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy